Advertisement
UK markets open in 3 hours 30 minutes

  • NIKKEI 225

    38,392.10
    +189.73 (+0.50%)
     

  • HANG SENG

    18,494.61
    +180.75 (+0.99%)
     

  • CRUDE OIL

    79.45
    +0.46 (+0.58%)
     

  • GOLD FUTURES

    2,318.90
    -3.40 (-0.15%)
     

  • DOW

    39,056.39
    +172.13 (+0.44%)
     

  • Bitcoin GBP

    49,182.49
    -983.16 (-1.96%)
     

  • CMC Crypto 200

    1,312.09
    +17.41 (+1.34%)
     

  • NASDAQ Composite

    16,302.76
    -29.80 (-0.18%)
     

  • UK FTSE All Share

    4,544.24
    +21.25 (+0.47%)
     
Money:

How to make a tax-free income

Tips for making money that won't be taxed

AstraZeneca two-in-one drug succeeds in lung disease test

Reuters - UK Focus

LONDON, March 18 (Reuters) - AstraZeneca (NYSE: AZN - news) said on Wednesday its experimental lung drug PT003 for chronic lung disease had proved successful in two final-stage Phase III trials, boosting hopes for the company's respiratory pipeline.

The drug, which AstraZeneca acquired after buying Pearl Therapeutics two years ago, combines a long-acting beta-2 agonist (LABA) and a long-acting muscarine antagonist (LAMA). AstraZeneca plans to file PT003 for approval commencing in 2015.

Rival firms also have LAMA/LABA drugs that are more advanced than PT003, but AstraZeneca's drug is administered with a pressurised meter-dose inhaler instead of a dry-powder inhaler, which may suit elderly patients in particular.

(Reporting by Ben Hirschler, editing by Louise Heavens)